Geisinger becomes first in U.S. to treat cancer patients with Accuray Synchrony® technology on the Radixact® and CyberKnife® S7™ Systems to better target radiation treatments
Geisinger has become the first hospital system in the U.S. to implement Accuray's Synchrony technology on its CyberKnife® S7™ and Radixact® Systems for advanced cancer care. This initiative aims to enhance the targeting of radiation therapy while minimizing damage to healthy tissue. Synchrony utilizes AI for real-time radiation adjustments based on tumor movement, leading to more efficient treatment. Geisinger's investment is part of their expansion at the Henry Cancer Center, where hypofractionated radiotherapy is now possible, offering higher doses with greater precision.
- Geisinger is the first U.S. hospital to use Synchrony technology on CyberKnife S7 and Radixact Systems.
- Synchrony technology enables real-time radiation adjustments, improving treatment accuracy.
- The implementation allows for hypofractionated radiotherapy, offering higher doses in fewer sessions.
- None.
WILKES-BARRE, Pa. and SUNNYVALE, Calif., May 3, 2021 /PRNewswire/ -- Geisinger continues to bring advanced cancer care closer to home as it is the first hospital system in the U.S. to offer Accuray Incorporated's (NASDAQ: ARAY) newest Synchrony® technology on both the CyberKnife® S7™ and Radixact® Systems to better aim radiation beams and minimize damage to non-cancerous tissue during treatment.
As part of Geisinger's expansion project at its Frank M. and Dorothea Henry Cancer Center, the health system recently began providing care using the one-of-a-kind Synchrony Motion Synchronization and Real-Time Adaptive Radiotherapy Technology on its CyberKnife S7 and Radixact Systems.
Synchrony uses artificial intelligence to adapt radiation treatment delivery in real-time to tumor movement during the treatment session, with the goal of delivering a more targeted radiation dose to the tumor, in less time, to improve outcomes. Synchrony is designed to correct the radiation beam if a tumor moves because of bodily processes such as breathing or digestion, as well as patient movement that may occur during treatment.
"We continue to invest in state-of-the-art technology, like Synchrony and CyberKnife, to provide the most advanced treatment options for our neighbors fighting cancer," said Dr. Anand Mahadevan, chairman of radiation oncology at Geisinger. "Along with our continued investment in the Henry Cancer Center, this is yet another way we're making better health easier for our patients and bringing these life-saving tools to the communities where they live right here in northeastern Pennsylvania."
Geisinger's team at the Henry Cancer Center at Geisinger Wyoming Valley Medical Center began treating patients using the CyberKnife® S7™ System in March 2020, the only such system in northeastern Pennsylvania. This latest advancement and upgrade with the Synchrony® technology allows Geisinger to offer hypofractionated radiotherapy – a shorter course of radiotherapy with higher radiation doses per fraction – without sacrificing the precision and accuracy required for high dose treatments.
"We congratulate the Geisinger team on their treatment milestone and look forward to continuing to partner with them to enhance cancer patient care," said Suzanne Winter, chief commercial officer and senior vice president, R&D at Accuray. "Accuray has been a pioneer in the development of high precision radiation therapy technology that supports the growing use of ultra-hypofractionated treatments. Synchrony technology was developed on the CyberKnife System more than 15 years ago, and based on overwhelming customer feedback and clinical evidence we applied this unique capability to the Radixact® System. While the two systems deliver radiation in different ways, they both are able to leverage the Synchrony real-time delivery adaptation to provide more precise, accurate treatments while maximizing patient comfort. We're inspired by how Geisinger is leading with this technology and positively changing the lives of patients and their families."
About Geisinger
Geisinger is committed to making better health easier for the more than 1 million people it serves. Founded more than 100 years ago by Abigail Geisinger, the system now includes nine hospital campuses, a 550,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. With nearly 24,000 employees and more than 1,600 employed physicians, Geisinger boosts its hometown economies in Pennsylvania by billions of dollars annually. Learn more at geisinger.org or connect with us on Facebook, Instagram, LinkedIn and Twitter.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.
CONTACT:
Accuray:
Beth Kaplan
408-789-4426
bkaplan@accuray.com
Geisinger:
Joseph Stender
570-271-6968
jhstender@geisinger.edu
View original content to download multimedia:http://www.prnewswire.com/news-releases/geisinger-becomes-first-in-us-to-treat-cancer-patients-with-accuray-synchrony-technology-on-the-radixact-and-cyberknife-s7-systems-to-better-target-radiation-treatments-301281635.html
SOURCE Accuray Incorporated
